Radiosensitizing Agent
Preclinical
Radiosensitizing Agent is one of 7 therapeutic programs targeting Muscle-Invasive Bladder Carcinoma. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
6
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
6 competitors in Muscle-Invasive Bladder Carcinoma
#DrugCompanyPhaseTrials
1Cisplatin-Based Neoadjuvant Chemotherapy
RRegina Elena Cancer Institute
Phase 3
Gemzar
Johnson & JohnsonPreclinical
Poly ICLC
CCelldex Therapeutics
Phase 1
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Adrucil
EElorac, Inc.
Preclinical
Mitosol
UUroGen Pharma Ltd.
Preclinical
Radiosensitizing Agent
UUniversity of Washington
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Radiosensitizing Agent. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Washington